Information Sheets about the Guidance for Institutional Review Boards and Clinical Investigators Issued by the United States Food and Drug Administration.
Guidance for Institutional Review Boards
Related posts
In Memoriam: The Sense and Sensibility of Dr. Jamie Lindemann Nelson
You can easily find Dr. Jamie Nelson’s decades of work and roughly 150 publications. What’s worth finding in them, and more valuable than the number of them, is the sense and sensibility with which that work, and Jamie’s life, was shot through. In 2009, I sat in Jamie Nelson’s office at Michigan State University, struggling […]
Brain Organoids: Reverse Zombies?
Imagine using stem cells to create a fragment of a human brain in a petri dish. It has no eyes to see, no mouth to speak, and no body to move. It’s just a part of a brain, designed to do one small aspect of what a brain does, like respond to stimulation or generate […]
From Epistemic Injustice to Epistemic Imagination: Reframing Older Age, Disability, and Dying in Bioethics
This editorial appears in the October 2026 Issue of the American Journal of Bioethics In Ageism, Ableism, and Epistemic Injustice: Tracing Absence and Construction in Bioethics and Public Health, Langmann and Goldberg demonstrate how ageism and ableism operate as epistemic forces that shape whose knowledge counts in bioethics and public health. Older adults and people […]
Individualizing Informed Consent: For Whom, and How Far?
This editorial appears in the October 2026 Issue of the American Journal of Bioethics In 2018, the U.S. federal guidelines were updated to require the reasonable person standard during informed consent in research settings. According to the standard, researchers must disclose to participants the risks, benefits, and purpose of the research that an “average person” […]